Synthetic GHRH analog — the only FDA-approved GHRH analog, originally indicated for visceral fat reduction in HIV lipodystrophy.
Tesamorelin (brand name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog. It is the only GHRH analog with FDA approval, originally indicated for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. It is now used off-label for body composition improvement, recovery, and anti-aging protocols.
Tesamorelin acts on the GHRH receptor in the anterior pituitary gland, stimulating the synthesis and release of endogenous growth hormone. This leads to increased GH pulses and downstream IGF-1 elevation, supporting visceral fat reduction, recovery, and tissue repair.
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Starting | 1–2 mg | Daily (bedtime) | Begin here to assess tolerance |
| Moderate | 4–6 mg | Daily | Standard protocol dose |
| High | 10–12 mg/week | Split across week | Advanced — monitor IGF-1 |
Cycle Length: 12–16 weeks minimum
Timing: Before bed
Route: Subcutaneous injection